Navigation Links
ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
Date:5/16/2008

- ANX-530 Demonstrates Statistically Significant Reductions in Selected

Safety Observations - Abstract to be published in 2008 Proceedings of the American Society of

Clinical Oncology

SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically significant reduction in general disorders and administration site conditions when compared to Navelbine(R) (p=0.014). In addition, in post hoc analyses, ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine (p<0.01). ANX-530 was determined generally to be safe and well-tolerated.

Detailed safety data from the registrational bioequivalence clinical study is available on the website of the American Society of Clinical Oncology (ASCO) at http://www.asco.org. The abstract, entitled "Tolerability and incidence of infusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution," will be published in the 2008 Proceedings of the American Society of Clinical Oncology in connection with ASCO's 2008 Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.

"We are encouraged by these data and pleased that our goal to improve the safety of vinorelbine has been observed in the clinic," stated Evan M. Levine, Chief Executive Officer and President of ADVENTRX. "The improvement in injection site reactions could translate into a real benefit for patients as well as healthcare practitioners."

A summary of all reported general disorde
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
3. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
4. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
10. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2008)...EAPOLIS, July 22 /- Nonin Medical, a ...tions for more than 20 years, has entered,the clin...y to measure,regional oxygen saturation. Today,s m...continuous monitoring of the regional blood oxygen...esting data and outcomes from an ongoing clinical ...
(Date:7/22/2008)...DA Meeting to Discuss Development Plan Completed S...-FirstCall/ -- Amarin Corporation,plc (NASDAQ: AM... with,officials at the U.S. Food and Drug Administ...elop AMR101 for the treatment of,hypertriglyceride...roceeding to Phase 3 with AMR101 in hypertriglycer...
(Date:7/22/2008)...-of-the-Art PET Study Confirms Tyrima Exhibits Exc...erties - - Results Support Initiation of Pha...N.C., July 22 /- CeNeRx BioPharma,In...cializing innovative,treatments for diseases of th... advance its lead candidate Tyrima(TM) into Phase ...
(Date:7/22/2008)...eoffrey Allan Will Stress the Importance to Patien...cs Approval Pathway, RICHMOND, Va., July 22 /PRNe... a developer of follow-on biologics and biopharmac...D., CEO of Insmed, will present at a,Congressional...e,significant need for establishing an approval pa...
Breaking Medicine Technology:Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Serum sodium predicts mortality 10 times higher in PAH patients 21781 1Serum sodium predicts mortality 10 times higher in PAH patients 21781 2New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 1New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 2New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 3New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 4New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 5New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 6New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 71 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9 11 21776 11 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9 11 21776 2Membrane complexes take flight 5975 1Membrane complexes take flight 5975 2
(Date:7/25/2008)... firm represents Pickerington man who contracted E... Kroger store , Columbus,...onaheyohioinjurylawyers.com [The Donahey Law Firm... central Ohio, has filed a product liability lawsu...ainst The Kroger Co., in connection with an E. col...
(Date:7/24/2008)...ital facility on Sand Canyon Avenue , ...08 -- Hoag Memorial Hospital Presbyterian has reac...l Estate Investment Trust headquartered in Long Be... Sand Canyon Avenue near the 405 freeway in Irvine...d by Tenet Healthcare Corporation (NYSE: THC) as I...
(Date:7/24/2008)...stCall/ -- ev3 Inc. (Nasdaq:,EVVV) today announced...and,year-to-date financial results. ev3 will now r...ancial results on Monday, July 28, 2008, after reg... a conference call and webcast at 7:30 a.m.,Centra...9, 2008. ev3,management will review its second qua...
(Date:7/24/2008)...ine Annual Report Experience it at http:/...f., July 24 /PRNewswire/ -- Are you an e-patient?,...users go online for,health information. Thanks to ...re personal health experiences, shop for health ca...Go to http://SutterHealth.org/annualreport ,and y...
Breaking Medicine News(10 mins):Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4
...edouble its efforts in the fight against HIV and A...tions program on HIV/AIDS, comes after Fiji's Mini...e in the number of people living with HIV and AIDS... The figures show that there were 36 new cases in...
...zil, Paraguay and Bolivia after an outbreak of den...fall //this season as a cause of the unusually rap...ncommonly warm weather has boosted the population ...the disease. Globally, it infects 50 million peo...
...Ministry of Health reported 789 suspected cases in...he country. // Ouargaye district has an attack rat...istricts, Banfora, Batie and Sapouy are in the ale...specimens have tested positive for Neisseria menin...
...als in the brain of mice were augmented, condition...ate in such animals. //This was reported by resear...alifornia. This finding could throw light in the ...cording to this study published in Nature, a combi...
Other Medicine News:
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
...w Binding, Graduated Pipet Tips - 0.5l - 10 L. Des... and protein binding. Non-reactive. Beveled and re...tion. RNAse & DNAse free. AVR100S is the Sterile R...0 is the Cell Rack packaged 96 tips/rack and 10 ra...
Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili
Like all Gilson disposable pipette tips, TowerPacks are available in a sterilized version. Each Sterilized TowerPack is individually wrapped in medical device-quality plastic to help protect tips fro
Medicine Products: